✦ LIBER ✦

Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment

✍ Scribed by Stephanie M. Sansone, Keith F. Widaman, Scott S. Hall, Allan L. Reiss, Amy Lightbody, Walter E. Kaufmann, Elizabeth Berry-Kravis, Ave Lachiewicz, Elaine C. Brown, David Hessl

Book ID: 113067955
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 366 KB
Volume: 42
Category: Article
ISSN: 1573-3432
DOI: 10.1007/s10803-011-1370-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-blind, placebo-controlled study o

Double-blind, placebo-controlled study ofL-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome

✍ Torrioli, M.G.; Vernacotola, S.; Mariotti, P.; Bianchi, E.; Calvani, M.; De Gaet 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 5 KB 👁 2 views

In this Issue/Abstract Thinking: Fragile

In this Issue/Abstract Thinking: Fragile X Syndrome and the Coming of Molecularly Targeted Treatments for Neurodevelopmental Disorders

✍ Veenstra-VanderWeele, Jeremy 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Developmental expression of FMRP in the

Developmental expression of FMRP in the astrocyte lineage: Implications for fragile X syndrome

✍ Laura K. K. Pacey; Laurie C. Doering 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 643 KB

## Abstract One of the most common causes of mental retardation in humans, Fragile X syndrome, results from the absence of FMRP, the protein product of the FMR1 gene. In the nervous system, expression of FMRP has been thought to be confined mainly to neurons as little research has examined FMRP exp

Double-blind, placebo-controlled crossov

Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin®) for the treatment of fragile X syndrome

✍ Strom, Charles M. ;Brusca, Rita M. ;Pizzi, William J. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 675 KB

## Abstract We conducted a randomized, double‐blind, placebo‐controlled crossover study of folinic acid therapy (dl‐Leucovorin®, 15 mg/day) or placebo for males with Fragile X (fra(x)) syndrome. Twenty‐one patients were enrolled in the study. The treatment periods were 3 months in length. Patients

A preliminary study of screening for ris

A preliminary study of screening for risk of autism in children with fragile X syndrome: testing two risk cut-offs for the Checklist for Autism in Toddlers

✍ D. J. Scambler; S. L. Hepburn; R. J. Hagerman; S. J. Rogers 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB